The one sector of the stock market that is cheap with upside today
Karen Firestone of Aureus Asset Management breaks down the case for biopharmaceuticals. Source link
Read More
Biogen Inc
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
Read More
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer's patients who take the therapy get
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read More
Investors want proof AI will aid drug discovery. Evidence may come in the second half
Nvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI
Read More
Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal
The move marks a sign the company is bulking up on rare disease medicines as its older multiple sclerosis drugs
Read More
Loads of analysts cut their price targets on these 10 stocks ahead of earnings
CNBC Pro screened for global stocks that have had their upside potential cut over the past seven days and ahead
Read More
These stocks were oversold during this week’s selloff and could be due for a bounce
Watch these stocks that could be due for a rebound after a selloff this week. Source link
Read More
Eli Lilly says FDA delays approval of Alzheimer’s drug in surprise move
The FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's
Read More